Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may prevent clots after leg surgery

NCT ID NCT07597239

Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 5 times

Summary

This study looks at whether a special blood test (TEG-PM) can guide doctors in adjusting blood-thinning medications for people who have had leg artery surgery for peripheral artery disease. About 130 adults will have their blood tested before and up to 9 months after surgery, and their medications (aspirin, clopidogrel, or ticagrelor) may be changed based on the results. The goal is to reduce the risk of dangerous blood clots forming in the treated leg.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

514 people

The number who actually took part.

Started

Nov 2020

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients requiring infrainguinal endovascular revascularization for peripheral atherosclerosis * Patients of age 60 or older Exclusion Criteria: * Planned open surgical revascularization (bypass grafting, endarterectomy) * Hybrid procedures involving a significant open surgical component * Contraindication to standard antiplatelet therapy * Pregnancy or breastfeeding * Inability to undergo serial venous blood sampling * Inability to provide informed consent * Technical failure to cross or treat the target lesion via an endovascular approach * Non-atherosclerotic pathology identified as primary etiology

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arterial occlusive diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arterial Occlusive Diseases peripheral arterial disease thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arterial occlusive diseases Peripheral arterial disease(PAD) Platelet inhibition Pru(platelet reactivity unit) Stent thrombosis Thromboelastography (TEG) Thrombosis

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.